Background {#s0005}
==========

Corticosteroids are the only treatment proven to reduce mortality from severe alcoholic hepatitis (SAH), though the benefit is short-lived.[@b0005] Several potential therapies are currently under evaluation in human clinical trials ([Table 1](#t0005){ref-type="table"}). These therapies target: i) malnutrition; ii) intestinal dysbiosis and its portal translocation; iii) bile acid production; iv) hepatocyte death; v) hepatocyte regeneration; and vi) life-threatening complications of the disease itself.Table 1**Active published clinical trials for alcoholic hepatitis listed by the U.S. National Library of Medicine at**[**clinicaltrials.gov**](http://clinicaltrials.gov){#ir005}**and European Clinical Trials Database at**[**EudraCT.ema.europa.eu**](EudraCT.ema.europa.eu){#ir010}.**PathologyTherapeutic targetTherapyTrial ID:**[**clinicaltrials.gov**](http://clinicaltrials.gov){#ir015}**, EudraCT, PMID**Portal translocation of gut microbiotaIntestinal dysbiosisRifaximinNCT02116556, EudraCT 2014-002264-33Oral vancomycin, gentamycin, meropenemNCT03157388Faecal microbiota transplantNCT03091010 NCT02458079Probiotics *Lactobacillus spp.*NCT01922895\
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Nutritional supplements {#s0010}
=======================

Malnutrition is common in this group of patients. Good nutrition is a central tenet of SAH management. Intensive nutrition delivered enterally or parenterally does not appear to confer clinical benefit.[@b0010] However, achieving a calorific intake \>21.5 kcal/kg per day is associated with a reduction in complications and mortality.[@b0010]

Portal translocation of gut microbiota {#s0015}
======================================

Intestinal dysbiosis has been implicated in a range of hepatic diseases. Alcohol consumption causes intestinal dysbiosis and impaired intestinal barrier function. Transfer of intestinal microbiota from humans with SAH to mice confers susceptibility to alcohol-induced steatohepatitis, which can be reversed by faecal microbiota transplantation from humans who drink heavily but do not develop SAH.[@b0015]

Current trials aim to improve bacterial dysbiosis using i) orally administered non-absorbable antibiotics (rifaximin or combined gentamicin, vancomycin and meropenem); ii) probiotics (*Lactobacillus rhamnosus* \[NCT01922895\] and *acidophilus* \[NCT02335632\]); or iii) faecal microbiota transplantation.

Enterohepatic circulation of bile acids {#s0020}
=======================================

SAH is characterised by marked biochemical and histological cholestasis. The farnesoid receptor (FXR) is a key regulator of bile acid synthesis. Receptor agonism also improves gut barrier function in mouse models of alcohol-related liver disease.[@b0020] Additional beneficial effects from FXR agonism in ameliorating portal hypertension have been suggested in rodent models of liver disease (reviewed in[@b0025]). Obeticholic acid (OCA) is a semi-synthetic agonist of FXR that has shown promise in non-alcoholic fatty liver disease[@b0030] and has established efficacy in primary biliary cholangitis.[@b0035] Clinical trial data are awaited (NCT02039219).

Immune dysfunction {#s0025}
==================

Immunotherapy for SAH is challenging because hepatic immunopathology exists concurrently with systemic immune defects. Accordingly, attempts to control hepatic immunopathology with systemic immunosuppressants, such as anti-TNFα[@b0040] or corticosteroid therapy,[@b0045] are hampered by high rates of infection that offsets clinical benefit. Pre-clinical data suggest that anti-IL-1β therapy does not confer such susceptibility to opportunistic infection and reduces hepatic inflammation, fibrogenesis, stellate cell activation and consequent portal hypertension (NCT02655510, NCT01903798, NCT01809132, EudraCT 2017-003724-79, NCT03775109).

Hepatocellular injury and repair {#s0030}
================================

Ethanol metabolism and immune responses lead to the generation of reactive oxygen species (ROS) that cause oxidative stress and hepatocellular damage. In single studies, the combination of intravenous *N*-acetylcysteine[@b0050] or oral metadoxine[@b0055] with corticosteroids appears to confer a survival benefit and is the subject of ongoing investigation (*N-*acetylcysteine \[NCT03069300\]; metadoxine \[NCT02019056, NCT02161653\]) along with S-adenosyl-[l]{.smallcaps}-methionine (SAMe) \[NCT00851981, NCT02024295\]. The efficacy of G-CSF, in part mediated via hepatic regeneration,[@b0060] has been suggested by small studies[@b0065] and several trials are in progress aiming to replicate these findings. Similarly, IL-22 has been ascribed hepatoprotective and pro-regenerative features; therapeutic agents are under clinical evaluation (NCT02655510).

Extrahepatic complications of alcoholic hepatitis {#s0035}
=================================================

*Infection*: up to 50% of SAH patients will develop infection during the acute illness and nosocomial infections reduce survival.[@b0070] Defective immune cells have been identified in the systemic circulation of patients with SAH and their presence is associated with the development of infection.[@b0075], [@b0080], [@b0085], [@b0090] Reversing these defects (NCT03069300) or predicting infections are attractive prospects. An alternative approach is to treat all SAH patients with broad-spectrum adjunctive antimicrobial therapy such as co-amoxiclav (NCT02281929) and ciprofloxacin (NCT02326103) and these two agents are currently under evaluation.

*Acute kidney injury*: kidney injury that occurs with SAH portends a poor prognosis. Primed immune cells release a plethora of inflammatory mediators, in particular ROS and nitric oxide, which cause vasodilatation in the splanchnic circulation. The vasopressin analogue terlipressin reduces this vasodilatation and is under investigation for SAH specifically.
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